Pharsight

Exelixis Inc patents expiration

1. Cabometyx patents expiration

CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(2 years from now)

US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(6 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use
Sep, 2024

(11 months from now)

US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US10039757 EXELIXIS INC C-Met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

US10034873 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2031

(7 years from now)

US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(8 years from now)

US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions
Jul, 2033

(9 years from now)

US11141413 EXELIXIS INC Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
Apr, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of advanced renal cell carcinoma; Treatment of d...

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic